AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Published: Saturday, February 28, 2026 at 1:13 pm

Faruqi & Faruqi Investigates Aquestive Therapeutics Following FDA Concerns

NEW YORK - Faruqi & Faruqi, LLP, a national securities law firm, has announced an investigation into potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST). The investigation follows a significant drop in Aquestive's stock price after the company revealed concerns raised by the U.S. Food and Drug Administration (FDA).

Shares of Aquestive Therapeutics experienced a sharp decline, approximately 40% intraday on Friday. This downturn was triggered by the company's disclosure of deficiencies identified by the FDA in its New Drug Application (NDA) for Anaphylm. Anaphylm is an experimental sublingual film designed to treat severe allergic reactions, including anaphylaxis.

The FDA's concerns reportedly prevent discussions regarding labeling and post-marketing requirements. This has raised questions about the application's approvability, particularly given the January 31, 2026, PDUFA action date.

Faruqi & Faruqi is encouraging investors who have suffered significant losses in Aquestive Therapeutics stock or options to contact partner Josh Wilson directly to discuss their legal options. Investors can reach Mr. Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). The law firm, established in 1995, has a history of recovering substantial funds for investors.

BNN's Perspective:

The situation highlights the inherent risks associated with investing in pharmaceutical companies, particularly those with products still undergoing FDA review. While the FDA's concerns are concerning for Aquestive Therapeutics and its investors, it is important to remember that the regulatory process is designed to ensure patient safety and efficacy. Investors should carefully consider the implications of such announcements and consult with financial advisors before making any decisions.

Keywords: Aquestive Therapeutics, AQST, Faruqi & Faruqi, FDA, Anaphylm, securities litigation, stock, investment, losses, investigation, NDA, allergic reactions, anaphylaxis, Josh Wilson, PDUFA, NASDAQ

Full Story